S. Kent

The 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma

B. O'connor, Z. Diamant, V. Norris, 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study

Dave Singh, J. Bentley, V. Norris, 2013, International journal of general medicine.

The effect of GSK2190915, a 5-lipoxygenase-activating protein inhibitor, on exercise-induced bronchoconstriction.

J. Bentley, V. Norris, M. Tarpay, 2014, Allergy and asthma proceedings.